CY1106749T1 - Χρηση ενος ppar-a αγωνιστη και μετφορμινης για την αντιμετωπιση της παχυσαρκιας - Google Patents

Χρηση ενος ppar-a αγωνιστη και μετφορμινης για την αντιμετωπιση της παχυσαρκιας

Info

Publication number
CY1106749T1
CY1106749T1 CY20071100972T CY071100972T CY1106749T1 CY 1106749 T1 CY1106749 T1 CY 1106749T1 CY 20071100972 T CY20071100972 T CY 20071100972T CY 071100972 T CY071100972 T CY 071100972T CY 1106749 T1 CY1106749 T1 CY 1106749T1
Authority
CY
Cyprus
Prior art keywords
metformin
ppar
agent
treat obesity
obesity
Prior art date
Application number
CY20071100972T
Other languages
English (en)
Inventor
Jean-Louis Junien
Alan Edgar
Evelyne Chaput
Original Assignee
Fournier Laboratories Ireland Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fournier Laboratories Ireland Limited filed Critical Fournier Laboratories Ireland Limited
Publication of CY1106749T1 publication Critical patent/CY1106749T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με τη συνδυασμένη χρήση ενός PPARα αγωνιστή και μετφορμίνης για την ελάττωση των τριγλυκεριδίων στον ορό.
CY20071100972T 2002-11-28 2007-07-20 Χρηση ενος ppar-a αγωνιστη και μετφορμινης για την αντιμετωπιση της παχυσαρκιας CY1106749T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02292940A EP1424070A1 (en) 2002-11-28 2002-11-28 Combination of a PPAR alpha agonist and metformin for decreasing the serum triglycerides
PCT/EP2003/013302 WO2004047831A2 (en) 2002-11-28 2003-11-26 Use of a pparalpha agonist and metformin for decreasing the serum triglycerides
EP03780062A EP1569634B8 (en) 2002-11-28 2003-11-26 Use of a ppar-alpha agonist and metformin for the treatment of obesity

Publications (1)

Publication Number Publication Date
CY1106749T1 true CY1106749T1 (el) 2012-05-23

Family

ID=32241358

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100972T CY1106749T1 (el) 2002-11-28 2007-07-20 Χρηση ενος ppar-a αγωνιστη και μετφορμινης για την αντιμετωπιση της παχυσαρκιας

Country Status (22)

Country Link
US (2) US20060142397A1 (el)
EP (2) EP1424070A1 (el)
JP (1) JP2006508995A (el)
CN (1) CN1777417B (el)
AT (1) ATE362362T1 (el)
AU (1) AU2003288175B2 (el)
BR (1) BR0316810A (el)
CA (1) CA2507894C (el)
CY (1) CY1106749T1 (el)
DE (1) DE60313886T2 (el)
DK (1) DK1569634T3 (el)
EA (1) EA009772B1 (el)
ES (1) ES2287546T3 (el)
HK (1) HK1077755A1 (el)
MA (1) MA27553A1 (el)
MX (1) MXPA05005707A (el)
NO (1) NO20052549L (el)
PT (1) PT1569634E (el)
SI (1) SI1569634T1 (el)
TN (1) TNSN05148A1 (el)
WO (1) WO2004047831A2 (el)
ZA (1) ZA200504345B (el)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
EP1457206A1 (en) * 2003-03-13 2004-09-15 Fournier Laboratories Ireland Limited Combined use of a fibrate and orlistat for the treatment of obesity
EP1559419A1 (en) * 2004-01-23 2005-08-03 Fournier Laboratories Ireland Limited Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention
FR2896160B1 (fr) * 2006-01-13 2008-04-25 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agonistes du ppar alpha.
US8883721B2 (en) * 2009-05-12 2014-11-11 Mcgill University Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
US9724381B2 (en) 2009-05-12 2017-08-08 The Administrators Of The Tulane Educational Fund Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
US9315546B2 (en) 2010-06-16 2016-04-19 The Administrators Of The Tulane Educational Fund Growth hormone secretatogue receptor antagonists and uses thereof
FR3050112B1 (fr) * 2016-04-15 2020-09-04 Soc Civ Immobiliere Gecinq Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques
CN107496397A (zh) * 2016-06-14 2017-12-22 重庆安格龙翔医药科技有限公司 一种二甲双胍与非诺贝酸的复合物及其制剂
FR3056908B1 (fr) * 2016-09-30 2019-04-19 Nashpharm Sel de metformine et d'elafibranor presentant une activite duale pour le traitement de l'obesite associee a la steato-hepatite non alcoolique (nash) et a l'hypertriglyceridemie
CN111374093A (zh) * 2018-12-28 2020-07-07 高倩 超级肥胖小鼠的构建与鉴定方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT323195B (de) * 1973-03-16 1975-06-25 Hurka Wilhelm Verfahren zur herstellung neuer salze von biguaniden
FR2275199A1 (fr) * 1974-06-19 1976-01-16 Cerpha (chloro-4 phenoxy) isobutyrate de dimethylbiguanide, son procede de preparation et medicaments contenant ce produit comme principe actif
US5190970A (en) * 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US5739106A (en) * 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
ES2241036T3 (es) * 1996-02-02 2005-10-16 MERCK & CO., INC. Procedimiento de tratamiento de diabetes y estados patologicos asociados.
AU4050797A (en) * 1996-08-02 1998-02-25 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
FR2774591B1 (fr) * 1998-02-12 2000-05-05 Lipha Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
US5942500A (en) * 1998-04-27 1999-08-24 Perry; Stephen C. Dietary composition to reduce dietary fats
FR2796940B1 (fr) * 1999-07-26 2005-04-08 Lipha Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
US6498193B2 (en) * 1999-12-22 2002-12-24 Trustees Of Dartmouth College Treatment for complications of type 2 diabetes
US6569879B2 (en) * 2000-02-18 2003-05-27 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
US20030092736A1 (en) * 2001-05-30 2003-05-15 Cheng Peter T. Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
WO2004034968A2 (en) * 2002-08-20 2004-04-29 The Regents Of The University Of California Combination therapy for controlling appetites

Also Published As

Publication number Publication date
CN1777417A (zh) 2006-05-24
EP1569634B8 (en) 2007-08-29
DE60313886T2 (de) 2008-01-17
JP2006508995A (ja) 2006-03-16
EA009772B1 (ru) 2008-04-28
EP1424070A1 (en) 2004-06-02
US20100144874A1 (en) 2010-06-10
EP1569634A2 (en) 2005-09-07
BR0316810A (pt) 2005-10-18
TNSN05148A1 (fr) 2007-05-14
DK1569634T3 (da) 2007-09-10
CA2507894A1 (en) 2004-06-10
EP1569634B1 (en) 2007-05-16
EA200500691A1 (ru) 2005-12-29
AU2003288175A1 (en) 2004-06-18
SI1569634T1 (sl) 2007-10-31
ZA200504345B (en) 2006-08-30
PT1569634E (pt) 2007-08-22
MA27553A1 (fr) 2005-10-03
ES2287546T3 (es) 2007-12-16
CA2507894C (en) 2011-01-04
NO20052549L (no) 2005-06-10
DE60313886D1 (de) 2007-06-28
CN1777417B (zh) 2010-10-06
US20060142397A1 (en) 2006-06-29
WO2004047831A2 (en) 2004-06-10
MXPA05005707A (es) 2005-07-26
ATE362362T1 (de) 2007-06-15
HK1077755A1 (en) 2006-02-24
WO2004047831A3 (en) 2005-02-24
AU2003288175B2 (en) 2008-11-13

Similar Documents

Publication Publication Date Title
CY1106749T1 (el) Χρηση ενος ppar-a αγωνιστη και μετφορμινης για την αντιμετωπιση της παχυσαρκιας
DE60327306D1 (de) Modifizierter russ
LTC2371392I2 (lt) Kalicheamicino darinio-nešiklio konjugatai
CY1106044T1 (el) Συνεργατικος αναλγητικος συνδυασμος οπιωδους αναλγητικου και αναστολεα της κυκλοοξυγενασης -2
CY2013043I1 (el) Ενωσεις 4-οξοκινολινης και χρησιμοποιηση αυτων ως αναστολεις της ενσωματασης του hiv
CY2014001I1 (el) Συνδυασμος αζελαστινης και φλουτικαζονης
CY1111613T1 (el) Μεθοδοι για την αντιμετωπιση της μολυνσης απο hiv
CY1108725T1 (el) Συνδυασμος ανταγωνιστου-nmda και αναστολεων ακετυλοχολινεστερασης δια την θεραπειαν της νοσου alzheimer
IS7689A (is) Fjölþátta lyfjaskammtaform
DE60324099D1 (de) Arzneistoffhaltiger tampon
CY1108748T1 (el) Χρηση αναστολεων της il-18 για την αντιμετωπιση και/η προληψη περιφερικων αγγειακων παθησεων
DE602004017927D1 (de) Zusammenbau von zwei Stent-Grafts
CY1110385T1 (el) Χρηση αναστολεων της il-18 για τη θεραπεια και/ή προληψη της αθηροσκληρωσης
DE60328490D1 (de) Nahtinstrumente
DK2289514T5 (da) Pramipexol-doseringsform til anvendelse én gang dagligt
CY1106992T1 (el) Καχαλαλιδη f και συναφεις ενωσεις
DE60335716D1 (de) Beschleuniger-zusammensetzung
DE60326373D1 (de) Gaspedal
NO20050689L (no) Terapeutisk anvendelse
CY1110538T1 (el) S-μιρταζαπινη για τη θεραπεια των εξαψεων
CY1113083T1 (el) Ασβεστιολυτικες ενωσεις
CY1107816T1 (el) Η χρηση ενος συνδυασμου ενος αναστολεα αρωματασης, μιας προγεστερονης και ενος οιστρογονου για τη θεραπεια της ενδομητριωσης
DE50310143D1 (de) Fahrpedal
NO20045213D0 (no) Korrosjonsbestandig ultralydavgiver
NO20044104L (no) Ikke-nukleoside reverstranskriptase-inhibitorer